In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about bullous pemphigoid:
• The clinical features and risk factors for developing bullous pemphigoid
 • How to differentiate bullous pemphigoid from other subepidermal blistering disorders
 • Management of bullous pemphigoid including:
 o Preferred first and second line agents
 o How and when to reduce treatment
 o What to do in severe and refractory cases
 
 Resources and further reading:
• European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated) (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220)
• British Association of Dermatologists’ guidelines for the management of bullous pemphigoid, 2012 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072)

Disclosure: 
Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series. 

Recorded date: 26 January 2024

Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references.